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with curative intent (66-70 Gy). We compared three different 
TPS: XiO® (CMS/Elekta, 2006-2010, step-and-shoot IMRT), 
Monaco® (CMS/Elekta, 2011-2012, step-and-shoot IMRT), and 
Eclipse™ (Varian Medical Systems, 2012-2013, RapidArc). We 
analyzed delineation volumes and several DVH parameters, 
including maximum and mean dose (Dmax and Dmean, 
respectively) and the volumes receiving 45 and 54 Gy (V45Gy, 
and V54Gy) of several organs at risk (OARs): salivary glands, 
oral cavity, spinal cord and brainstem. All data were 
retrieved automatically from Maastro Clinic’s Data 
Warehouse that contains data from the TPS, R&V systems, 
treatment machines and electronic medical file. Based on the 
DICOM-RT data from the TPS, all relevant DVH data were 
recomputed using the same DVH engine for all different 
TPS’s. 
Results: The volumes of the OARs were relatively stable 
thoughout the study period with differences of 5-10%. The 
results of the analysis of DVH parameters are given in table 
1. 
 
 
The average Dmean of both parotid glands reduced 
significantly from XiO, to Monaco, and Eclipse. The 
percentage of parotid glands receiving a Dmean <26 Gy 
increased by approximately 30%: from 45% with XiO to 32% 
with Eclipse. Similarly, also for the Oral Cavity an improved 
sparing was achieved using Monaco and Eclipse. No 
statistically significant changes in dose to the submandibular 
glands were observed, due to the proximity of this OAR to 
the target-volume.  
Average Dmax and V45Gy to the spinal cord were both also 
significantly lowered, indicating facilitated sparing with the 
VMAT technique employed in Eclipse. The average Dmax to 
the Brainstem again showed similar reductions with VMAT. 
Conclusions: Using an automated analysis we have 
demonstrated improved sparing of several important OARs 
over time with the implementation of modern state-of-the-
art TPS and new treatment techniques in a large population-
based planning study. Analysis of target coverage is ongoing. 
 
PO-0790 
Changes in acute response to radiation after 
implementation of new national guidelines for head and 
neck cancer 
C.R. Hansen1, A. Bertelsen1, R. Zukauskaite2, J.G. Eriksen3, 
C. Brink2, J. Johansen3 
1Odense University Hospital, Laboratory of Radiation Physics, 
Odense, Denmark 
2University of Southern Denmark, 
Institute of Clinical Research, Odense, Denmark 
3Odense University Hospital, Department of Oncology, 
Odense, Denmark 
 
Purpose/Objective: New national guidelines (GL) for 
radiotherapy (RT) of head and neck cancer (HNC) were 
implemented at the beginning of 2013. One purpose of the 
new GL was to nationally standardise the expansion from GTV 
to high risk CTV (CTV1). This standardisation has resulted in 
change of volume of CTV1 for most institutions which 
previously used different margins. Change in CTV1 volume 
definition could influence the risk and time evolution of 
adverse effects e.g. mucositis. This study investigates change 
in acute response during RT in a centre where GTV to CTV1 
margin was increased from 0 to 5mm. 
Materials and Methods: All patients (n=592) receiving 
curative RT for HNC from Jan 2011 to Sep 2014 were 
included, 292 patients treated according to the old GL and 
300 according to the new GL. Tumour doses were 66-68 Gy in 
33-34 fx with 5 or 6/10 fx/w. All were treated with IMRT 
except for simple glottic tumours. Acute skin and mucosal 
reactions were scored weekly during RT, and 2 and 8 weeks 
after (0 none, 1 erythema, 2 dry desquamation/patchy 
mucositis, 3 wet desquamation/confluent mucositis, 4 
ulceration). Use of analgesics was recorded equivalently on a 
5-point scale. Clinical endpoints were dichotomized, grade 0-
1 vs 2+ or 0-2 vs 3+. 
Potential change in actuarial cumulative incidence (One 
minus the Kaplan Meier estimator) of mucositis was tested 
using the log-rank test. To stratify for the potential effect 
between non-accelerated (5 fx/w) and accelerated (6/10 
fx/w) treatments, a Cox regression analysis including the 
covariates: acceleration, old/new GL, and their interaction 
product was performed. Potential differences between 
patient demographics were tested using a chi-square test. 
Results: The new GL increased the risk of grade 2+ mucositis 
during RT (p = 0.02) as demonstrated by a ~20%-point 
increase at the end of RT for the non-accelerated group, but 
not in the accelerated group. In Cox regression, all covariates 
were significantly associated with grade 2+ and 3+ mucositis 
(acceleration, p<0.001; GL, p=0.02). The interaction term 
was negative indicating that the impact of GL on acute 
response was dependent on the fractionation schedule 
(Figure). For skin reactions and use of analgesics, there were 
no observed differences between the old and the new GLs. 
No differences in demographics (gender, age, site, stage) 
were observed between the groups 
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Conclusions: For the non-accelerated RT, the new GL 
increased the risk of acute mucositis by about 20%-point at 
the end of RT. This study implies that mucosal repopulation 
is compromised by the expanded CTV1 volumes during non-
accelerated RT. During accelerated RT, the risk of grade 
2+/3+ mucositis was not related to GL, plausibly due to a 
high dose intensity eliminating mucosal repopulation. 
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Purpose/Objective: IMPT is vulnerable to uncertainties due 
to sensitivity of the location of Bragg peaks. Dose delivery 
can for instance be influenced by anatomical changes, range 
and setup uncertainty. Uncertainties can be modeled with a 
number of alternative scenarios. We introduce a novel 
method for interpretation of these scenarios using TCP and 
NTCP models. 
Materials and Methods: Thirteen patients were selected 
from an imaging protocol for photon treatment based on 
location in the oropharynx and bilateral neck treatment. Two 
IMPT plans were generated where either the original PTV or 
the CTV was used as a planning objective. The prescribed 
dose was 54 Gy in 35 fractions with a SIB of 70 Gy. For eight 
uncertainty scenarios the plans were recalculated: two for 
range over- and under-shoot of 3%, six for shifts of 3 mm 
along each translational axis. Additionally, the average of the 
shift recomputations () was calculated. TCP was calculated 
with a TD50 of 60 Gy and gamma50 of 4. Fifteen NTCP 
endpoints were evaluated with models derived from 
literature. A weighted average (W_Avg) was calculated with 
an estimated probability contribution of 7% for the nominal, 
16,5% for each range scenario and 10% for each shift 
scenario. For each endpoint we evaluated the worst case and 
the percentage of patients with a threshold violation of 5% 
decrease in TCP or increase of NTCP for at least one 
scenario. Additionally, to assess the effect of random errors, 
we evaluated the scenario and the W_Avg, averaged over all 
patients. 
Results: All plans had at least one threshold violation 
representing a risk of decreased TCP or increased NTCP in the 
presence of uncertainties. We observed less TCP decrease in 
the PTV plans compared to the CTV plans (table 1). Nominal 
NTCP values and uncertainties were generally higher in PTV 
plans. Endpoints with a high risk of increased NTCP in the 
presence of uncertainties were xerostomia and mandible 
necrosis (table 1). Of the critical neurological endpoints, 
brainstem injury exceeded 5% NTCP increase in at least one 
scenario in 3 patients. The scenario (fig 1) was close to zero 
for all endpoints with a SD for CTV plans of 0.5% for both TCP 
and NTCP, for PTV plans the SD was 0.2% for TCP and 0.7% for 
NTCP. The W_Avg was also low, except for TCP endpoints in 
CTV plans where it reached -5% (table 1, fig 1).  
 
 
